Principal Investigator
Denise Pereira
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20240449
Clinical Trial Summary
A Phase 2/3, Open-Label, Randomized, Controlled, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, Versus Ongoing Standard-Of-Care Immunosuppressive Therapy in Patients with Generalized Myasthenia Gravis (KYSA-6)
Phase
Phase II
Funding Agency/Sponsor
Industrial
Disease
Transplant/cellular therapy
Contact Information
Phone Number
305-243-2647